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Background: The aim of this pilot study was to evaluate whether the uptake of 89Zr-bevacizumab in non-small cell
lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor 89Zr-bevacizumab
uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored.
Methods: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4 ± 0.9 MBq
(mean ± SD) 89Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB).
Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was
correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak).
Results: Zr-bevacizumab uptake (SUVpeak) was approximately four times higher in tumor tissues (primary tumor
and metastases) than in non-tumor tissues (healthy muscle, lung, and fat) on days 4 and 7. A positive trend but no
significant correlation could be found between SUVpeak and OS or PFS.
Conclusions: This pilot study shows that 89Zr-bevacizumab PET imaging in NSCLC is feasible. Further investigation
to validate this technique as a predictive biomarker for selecting patients for bevacizumab treatment is warranted.
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Vascular endothelial growth factor (VEGF) is an important
mediator in non-tumoral and tumoral angiogenesis.
VEGF-A, one of the five members of the VEGF family and
generally referred to as VEGF, is overexpressed in many
tumors [1,2]. In response to hypoxia, cells of mesenchymal,
stromal, and epithelial origin (e.g., myocytes, blood platelets,
and stromal cells in tumors) show paracrine secretion of
VEGF-A. This increases VEGF-A concentrations locally in
the tumor, causing a strong pro-angiogenic stimulus. The
binding of VEGF-A to VEGF receptor subtypes 1 and 2
(VEGFR1 and VEGFR2), both transmembrane monomers
expressed on vascular endothelial cells, causes dimerization
of the VEGFR1/2 monomers, leading to the activation of
intracellular pro-angiogenic signaling pathways [3-6]. Also,* Correspondence: idrisbahce@hotmail.com
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described [3,7,8].
The addition of bevacizumab, a monoclonal antibody
directed against VEGF-A, to cytotoxic chemotherapy
improves tumor response rates and provides a survival
advantage over chemotherapy alone in several malignancies
[9-12]. A phase III study showed a survival benefit for
patients with non-small cell lung cancer (NSCLC) treated
with carboplatin-paclitaxel-bevacizumab compared with
chemotherapy alone [13]. However, on an individual basis,
it is unclear who would benefit from bevacizumab therapy,
as predictive markers are lacking, despite a large body of
clinical research available to date.
Imaging tumor uptake of radiolabeled bevacizumab in
patients using positron emission tomography (PET) may
provide such a predictive marker, as PET imaging
enables in vivo monitoring of physiological processes. To
date, several clinical studies have been performed using
antibodies with 89Zr labeling. In these studies, positiven Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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response discussed [14-17]. The aim of this pilot study
was to evaluate whether 89Zr-bevacizumab enables
visualization of NSCLC tumors and to assess the ranges of
tumor-to-background ratios and standardized uptake values.
Additionally, the correlation between 89Zr-bevacizumab
uptake and tumor response following treatment with a




In this prospective pilot study, patients with stage IV
adenocarcinoma of the lung who were scheduled for
combined carboplatin-paclitaxel-bevacizumab treatment
were enrolled. Inclusion criteria were histologic diagnosis
of non-squamous NSCLC, age of 18 years or older,
performance status of 0 to 2 (WHO), a life expectancy of
at least 12 weeks, and presence of at least one NSCLC
lesion within the chest of at least 1.5-cm diameter as
measured by computed tomography (CT). Exclusion
criteria included claustrophobia, pregnancy, lactation, and
use of concurrent or previous treatment with anticancer
drugs within 30 days prior to scanning. The patients gave
informed consent, and this study was approved by the
Medical Ethics Review Committee of the VU University
Medical Center.
Imaging
Prior to the start of therapy, the patients underwent
PET/CT scans using [18 F]fluorodeoxyglucose (FDG) and
89Zr-bevacizumab.
Therapy
As scheduled prior to inclusion in this study, the patients
received treatment with carboplatin (area under the
concentration-time curve of 6.0 mg/mL/min)-paclitaxel
(200 mg/m2 of body surface area)-bevacizumab (15 mg/kg)
and continuation maintenance bevacizumab upon
non-progression after 4 cycles. Chemotherapy was given
every 21 days until disease progression or unacceptable
toxicity [13].
Preparation of 89Zr-bevacizumab
Bevacizumab was labeled with zirconium-89 using
N-succinyl-desferrioxamine (N-suc-Df ) as described
previously [18,19]. All procedures were performed under
aseptic conditions in a shielded laminar flow cabinet. In
short, desferrioxamine (Desferal (Df), Novartis, Basel,
Switzerland) was converted to N-succinyl-Df. Next, the
hydroxamate groups were blocked with iron, and the
succinic acid group converted to its tetrafluorophenol
ester. The resulting Fe-N-suc-Df-TFP ester was reacted
with bevacizumab under basic conditions (pH 9.5 to 9.7)for 30 min at room temperature. Subsequently, iron was
removed using an excess of ethylenediaminetetraacetic
acid (EDTA) for 30 min at 35°C, and the resulting
N-suc-Df-bevacizumab was purified over a e and
radiolabeled with 89Zr for 60 min in HEPES buffer at room
temperature. Finally, 89Zr-N-suc-Df-bevacizumab was puri-
fied over a PD-10 column using 5 mg/mL gentisic acid in
0.9% NaCl (pH 4.9 to 5.4). The mean labeling efficiency
was 71.1% ± 5.3%. The product was formulated and filter
sterilized to 5 mg bevacizumab and 37 MBq Zr-89 per
patient injection. These procedures resulted in a sterile
final product with endotoxin levels <2.5 EU/mL. The
radiochemical purity was >97% according to iTLC and
HPLC, and the immunoreactivity as determined by an
ELISA assay was >75%, which is optimal for this assay.
PET scanning
All patients underwent a routine FDG PET/CT scan
within 4 weeks prior to starting therapy. One week
prior to therapy, the patients were injected intravenously
with 36.4 ± 0.9 MBq 89Zr-bevacizumab, and 10-min static
PET/CT scans of the thoracic NSCLC lesion were per-
formed on days 4 and 7 post-injection. These parameters
were based on previous 89Zr-trastuzumab analysis, show-
ing appropriate doses and timing for visualization and
quantification of uptake in HER2-positive tumors to be
37 MBq and days 4 to 5 after injection, respectively [20].
The scans were performed on a Gemini TF-64 PET/CT
scanner (Philips Medical Systems, Cleveland, USA). PET
data were normalized, and all appropriate corrections
were applied for dead time, decay, randoms, and scatter.
Reconstruction of PET data was performed using the
BLOB-OS-TF reconstruction algorithm with CT-based
attenuation correction, resulting in a final voxel size
of 4 × 4 × 4 mm3, matrix of 144 × 144 × 45, and a spatial
resolution of 5 to 7 mm full-width at half maximum [21].
Additional smoothing was performed, as this was shown
to optimize quantitative accuracy and harmonized image
quality [22].
89Zr-bevacizumab uptake analysis
FDG PET/CT scans were used to identify the exact loca-
tion of the tumors. The PET data were analyzed using
in-house-developed analysis tools within the IDL environ-
ment (Interactive Data Language Virtual Machine 6.2, RSI
Inc., Boulder, CO, USA). Volumes of interest (VOI) were
drawn manually on the CT images around the contours of
the primary tumor (PT) and, if present, lymph node
metastases (LNM) and non-lymph node metastases
(NLNM). Additionally, VOI were drawn within the
descending aorta (AD) and non-tumor tissue muscle (M),
healthy lung (HL), and fatty tissue (FT). Standardized
uptake value (SUV) parameters were calculated by
normalizing VOI activity concentrations to injected
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diameter positioned around the voxel with the highest
uptake) and SUVmean (mean activity in VOI/cc) from the
AD VOI to calculate the tissue-to-blood ratio (TBR).
SUVpeak and TBR for the abovementioned VOI were then
compared for the scans at days 4 and 7.Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS for Windows 15.0, SPSS, Inc.). Correlations were
explored using Spearman’s correlation coefficient (rs). A
two-tailed probability value of P < 0.05 was considered
significant. Values in the text and tables are presented as
mean ± standard deviation (SD) unless stated otherwise.Results
Seven patients were included in this study. The patient
characteristics are summarized in Table 1. Nine mediastinal
LNM were identified using FDG PET/CT scans within the
thoracic field of view. Six patients showed NLNM. All
tumor lesions showed visible 89Zr-bevacizumab uptake. To
illustrate the findings as reported below, typical examples of
fused PET/CT images using FDG and 89Zr-bevacizumab in
three NSCLC patients are provided in Figure 1.
In all tumorous tissues (PT, LNM, and NLNM),
89Zr-bevacizumab uptake (SUVpeak) was approximately
four times higher than those in non-tumorous tissues
(M, HL, and FT) on days 4 and 7, as shown in Table 2.
For tumorous tissues, the SUVpeak in NLNM and LNM
was approximately 54% and 26% higher as compared to
that in PT on day 4, and 49% and 19% higher on day 7,
respectively (see Figure 2).
Remarkably, on day 4, activity concentration in
blood (AD) was approximately the same as that in
the PT, while the healthy tissue activity was clearly









1 F 56 RLL - AC Yes
2 M 51 RUL Peritoneum AC Yes
3 M 59 RLL Bone AC Yes
4 M 61 RLL Bone LCC Yes
5 F 54 RLL Bone AC Yes
6 F 69 RH Pericardium AC Yes
7 M 51 LH Bone AC No
Evaluable metastases are non-primary lesions, located within the PET field of view.
who died before bevacizumab maintenance therapy could be administered. The be
all patients. aTwo patients developed clinical disease progression before radiologica
Sites of radiological progression are shown. PFS and OS were calculated in weeks, b
AC, adenocarcinoma; CR, complete response; F, female; LCC, large cell carcinoma; L
overall survival; PC, peritonitis carcinomatosa; PD, progressive disease; PFS, progress
RLL, right lower lobe; RUL, right upper lobe; SDC, salivary duct carcinoma.However, between days 4 and 7, tumor TBR increased
from 1.23 ± 0.4 to 2.2 ± 1.2.
SUVpeak correlated strongly between days 4 and 7, as
indicated by an rs of 1 (P < 0.001). Figure 3 shows the
correlation between days 4 and 7 for SUVpeak.
As shown in Figure 4, correlations between tumor
SUVpeak and outcome parameters showed a positive
trend, but did not reach statistical significance. SUVpeak
showed weak correlation with both PFS and OS on days
4 and 7. (rs was 0.64 with a P = 0.139 for both PFS and
OS on days 4 and 7, respectively).
Discussion
Visualization of tumor lesions
Prior to this study, it was unclear whether NSCLC
tumors could be imaged by 89Zr-bevacizumab. The
results of this pilot study show that all tumor lesions
(PT, LNM, and NLNM) had a higher 89Zr-bevacizumab
uptake as compared to non-tumor background tis-
sues, allowing for visualization and analysis of tumor
89Zr-bevacizumab uptake.
This increased uptake may be caused by accumulation
of VEGF in the tumor, due to high paracrine expression
and subsequent binding to extracellular matrix glycopro-
teins such as heparan sulfate proteoglycans (HSPG)
and neuropilins (NRP). These glycoproteins act as
non-signaling co-receptors that facilitate binding of
VEGF to VEGFR molecules [6]. Another mechanism that
may contribute is the internalization of 89Zr-bevacizumab
into cells within the tumor. After internalization, the 89Zr
label may become trapped in the lysosomes and show up
on the PET scan [23].
Our findings are in accordance with the limited
number of publications of previous preclinical and
clinical data showing that high-VEGF-A-expressing
tumors are associated with high tumor-to-background










PR LLL 56 79
PR PC 13 17
PR RULa 27 48
CR RA 35 63
PR Brain 54 74
PR MC 34 60
PD Livera 3 3
All patients received bevacizumab maintenance therapy, except for one patient,
st tumor response to chemotherapy is shown. Progressive disease was seen in
l progression. One patient developed progression due to brain metastasis.
etween start of chemotherapy and date of progression and death, respectively.
H, left hilum; LLL, left lower lobe; M, male; MC, meningitis carcinomatosa; OS,
ion-free survival; PR, partial response; RA right adrenal gland; RH, right hilum;
Figure 1 Fused PET/CT images using FDG (A) and 89Zr-bevacizumab at day 4 (B) and day 7 (C). Per scan, an axial and coronal slice is
shown. The color scale, indicating Becquerels per milliliter (BQML), ranges from 0 to a maximum value that corresponds with a SUV value of 6. In
patient 1, a large tumor in the right lower lobe is seen. There is increased FDG uptake in the outer rims of the tumor and reduced uptake in the center
of the tumor (probably due to necrosis). The 89Zr-bevacizumab image on day 4 also shows high uptake in the outer rims of the tumor (T1) and high
blood activity concentration (aorta descendens (AD) and heart chambers (H)). Low uptake is found in non-tumor tissues, such as healthy lung, fat, and
muscle. The 89Zr-bevacizumab image on day 7 shows high uptake in the outer rims of the tumor but low uptake in healthy tissues as well as low
blood activity concentrations. In patient 2, the FDG scan shows increased uptake in both the primary tumor in the right upper lobe and enlarged
mediastinal lymph node metastases. Interestingly, the 89Zr-bevacizumab images only show increased uptake in the lymph node metastases (LN), while
the uptake in the primary tumor (T2) on both days 4 and 7 is faint. In patient 3, the primary tumor, the mediastinal lymph node metastases, and rib
metastasis all show increased FDG uptake. The 89Zr-bevacizumab scans on days 4 and 7 show the highest uptake in the rib metastasis (M) and the
primary tumor (T3), and moderate to high uptake is seen in the liver (L).
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xenografts had a higher uptake of 89Zr-bevacizumab
than of 89Zr-labeled IgG, which served as a control.
In a follow-up study, the same researchers found that






(2.1 to 6.9) (2.1 to 12.1) (2.9 to 14.5)
TBR
1.2 1.1 1.2




(0.7 to 4.9) (1.0 to 9.0) (1.1 to 9.7)
TBR
0.8 1.6 1.9
(1.0 to 4.0) (1.1 to 15.3) (0.9 to 16.5)
AD, aorta descendens; LNM, lymph node metastases; NLNM, non-lymph node metasensitive) A2780 ovarian tumor xenografts after 2 weeks
of antitumor therapy (using NVP-AUY922), while in the
therapy-resistant CP70 xenografts, 89Zr-bevacizumab uptake
did not change. van der Bilt et al. [25] showed a decrease




3.9 1.0 0.6 0.8
(1.7 to 4.9) (0.4 to 1.1) (0.3 to 0.7) (0.5 to 1.4)
0.3 0.2 0.3
(0.1 to 0.3) (0.1 to 0.2) (0.2 to 0.3)
1.4 0.5 0.4 0.4
(0.9 to 3.5) (0.2 to 1.3) (0.1 to 0.6) (0.2 to 1.1)
0.5 0.3 0.4
(0.3 to 0.6) (0.1 to 0.4) (0.2 to 0.6)
stases; PT, primary tumor; TBR, tumor-to-blood ratio. Median (range) is shown.
Figure 2 Comparison of 89Zr-bevacizumab SUVpeak and TBR in different tissues. The values were compared at day 4 (open bars) and day 7
(black bars). AD, aorta descendens; FT, fatty tissue; HL, healthy lung; LNM, lymph node metastasis; M, muscle; NLNM, non-lymph node metastasis;
PT, primary tumor; TBR, tumor-to-blood ratio.
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89Zr-bevacizumab uptake remained unchanged in
other organs, matching ex vivo measures of VEGF-A
levels [19,24,25]. Recently, a first clinical study using
89Zr-bevacizumab was reported. In breast cancer patients,
tumors with elevated VEGF-A levels showed higher
89Zr-bevacizumab uptake than the background of healthy
breast tissue [26].
We found that tumor-to-background ratios were
high at days 4 and 7; however, tumor-to-blood ratios
were higher on day 7, due to a relative decrease of
blood activity concentrations as compared to tumor
activity concentrations. However, image quality at day
7 was hampered due to physical decay of the tracer.
The optimal time for 89Zr-bevacizumab seems to be
between 4 and 7 days post-injection.
Lymph node metastases and especially NLNM showed
higher uptake than pulmonary lesions. This may be
caused by the fact that pulmonary lesions suffered moreFigure 3 Comparison of tumor 89Zr-bevacizumab uptake
(SUVpeak) on days 4 and 7. A correlation coefficient (rs) of 1 (P< 0.001)
was found.from breathing movement-induced partial volume
effects than LNM and NLNM, which were relatively
fixed to bone and peritoneum. Although all tumoral
lesions were visible in this study, the quantification of
uptake in small-volume lesions needs to be interpreted
with caution, as these tumors suffer even more from this
partial-volume-induced underestimation of tracer uptake.
Clinical outcome
Although our results did not show a significant correlation
between tracer uptake and PFS, a positive trend was
observed. As tumor 89Zr-bevacizumab uptake may
represent the level of tumor VEGF, this technique
might offer a predictive biomarker for bevacizumab
treatment efficacy. At present, there is an absence of
clinically useful predictive biomarkers. For example,
several blood biomarkers, such as VEGF-A and NRP-1
using newly developed sensitive assays, have been
proposed to predict bevacizumab treatment efficacy, but
their value is still the subject of debate [6,27].
Limitations
As this was a pilot study, only a limited number of
patients were included. However, the results obtained
were consistent for all patients, indicating that larger
clinical trials are warranted.
Another limitation was the absence of arterial blood
sampling for blood and plasma activity and metabolite
analysis, which could have provided a more accurate
quantification of tracer uptake. However, because patients
already underwent several PET/CT scans, additional blood
sampling for research purposes was considered too high a
burden. Furthermore, previously published data show
a good correlation between image-derived activity
from 89Zr-labeled antibodies and blood activity [15,17].
Additionally, 89Zr-bevacizumab was found to be highly
stable in plasma, as only a 6% decrease in protein-bound
radioactivity was seen after 168 h (stored in serum at
Figure 4 Correlations between SUVpeak and clinical outcome (PFS and OS). The correlations are for day 4 (open circles) and day 7 (black
squares). Correlation coefficients were not statistically significant for both PFS and OS, with rs of 0.64 (P = 0.139) at days 4 and 7, respectively. PFS,
progression-free survival; OS, overall survival.
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in all patients, no extra tumor biopsy was taken prior
to scanning for VEGF-A staining, again because this
was considered too burdensome.
Future perspectives
The results of this study show tumor specific uptake
of 89Zr-bevacizumab. Future studies should consider not
to include small lesions that could suffer from partial
volume effects. Furthermore, the optimal timing should
be investigated, as this can be expected to be between day
4 and day 7 post-injection. To better understand the
physiological processes causing tracer accumulation,
concurrent pathology data (e.g., angioproliferative markers)
should be assessed by taking biopsies prior to scanning.
Quantification of uptake may be improved by using blood
sampling for plasma radioactivity assessment.
The effect of perfusion on 89Zr-bevacizumab should
be analyzed. In this study, an assessment of tumor
blood perfusion, e.g., with [15O]H2O PET scan, was
not performed. Using [15O]H2O PET scans, van der
Veldt et al. [28] showed that the intratumoral distri-
bution of docetaxel followed the tumor perfusion patterns.
Therefore, tumor perfusion data may have provided
additional understanding of the distribution of tumoral
89Zr-bevacizumab uptake.
89Zr-bevacizumab PET may be used as an imaging
agent, as tracer uptake showed a trend towards a
positive correlation with PFS and OS. It should be
noted that patients were treated with carboplatin-
paclitaxel-bevacizumab (CPB) followed by bevacizu-
mab maintenance therapy. PFS was the result of both
CPB therapy and bevacizumab. In future studies,
89Zr-bevacizumab scans should ideally be performed
at two time points, i.e., prior to CPB therapy and also
prior to bevacizumab maintenance therapy. This isbecause the post-CPB-altered tumor VEGF status is
unknown; however, this new post-CPB VEGF status
may be a better predictor for sensitivity to subsequent
bevacizumab maintenance therapy.Conclusions
This pilot study demonstrates that 89Zr-bevacizumab
PET imaging in tumors is feasible. Larger studies are
needed to validate and substantiate these findings.
89Zr-bevacizumab PET merits further investigation, aiming
to evaluate its use as a predictive imaging biomarker.
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